Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00
Provider: Jefferson Research
$20.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Angiodynamics Inc Issues FY 2014 Guidance In Line With Analysts' Estimates; Issues Q1 2014 Guidance; EPS Guidance Above Analysts' Estimates


Thursday, 11 Jul 2013 04:01pm EDT 

Angiodynamics Inc announced that for fiscal 2014, it expects to deliver modest sales growth ranging from $346 million to $352 million, reflecting a 3% increase at the top end of the range. Anticipate adjusted earnings per share (EPS) to be in the range of $0.31-$0.35 and adjusted EPS, excluding amortization, to be in the range of $0.61-$0.65. The Company expects net sales to range from $81 million to $84 million in the first quarter of 2014, Adjusted EPS is expected to be in the range of $0.02-$0.04 and in the range of $0.10-$0.12 for adjusted EPS excluding amortization. According to I/B/E/S Estimates, analysts are expecting the Company to report revenues of $350 million and EPS of $0.33 for fiscal 2014; revenues of $84 million and $0.08 for the first quarter of 2014. 

Company Quote

14.75
0.13 +0.89%
11 Jul 2014